20 Jul Laverock Therapeutics
Tom Payne, Ph.D., Chief Operating Officer
Oct. 7 | 12:15pm | FLW Ballroom F
London, UK
(Private)
Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock’s product focus encompasses iPSC derived macrophages engineered to polarise to a pro-inflammatory state in the tumour microenvironment, and donor-derived CAR-T cells for hard-to-treat cancers where multiple check-point pathways can be conditionally silenced (for example, only when the CAR-T cell is engaged with its target) providing improved efficacy without negative affects on cell fitness. In addition, we are developing the platform for in vivo editing to achieve tunable gene silencing in genetic diseases where gene dosage needs to be tightly controlled (over or under expression is detrimental).
